Trade Heron Therapeutics, Inc. - HRTX CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.05 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.02354% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001318% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 2.23 |
| Open | 2.12 |
| 1-Year Change | -22.34% |
| Day's Range | 2.1 - 2.2 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Mar 28, 2025 | 2.23 | -0.07 | -3.04% | 2.30 | 2.30 | 2.20 |
| Mar 27, 2025 | 2.29 | 0.04 | 1.78% | 2.25 | 2.32 | 2.24 |
| Mar 26, 2025 | 2.27 | -0.04 | -1.73% | 2.31 | 2.35 | 2.25 |
| Mar 25, 2025 | 2.32 | -0.09 | -3.73% | 2.41 | 2.41 | 2.30 |
| Mar 24, 2025 | 2.40 | 0.01 | 0.42% | 2.39 | 2.43 | 2.35 |
| Mar 21, 2025 | 2.36 | 0.00 | 0.00% | 2.36 | 2.40 | 2.31 |
| Mar 20, 2025 | 2.37 | -0.03 | -1.25% | 2.40 | 2.43 | 2.34 |
| Mar 19, 2025 | 2.42 | -0.03 | -1.22% | 2.45 | 2.53 | 2.39 |
| Mar 18, 2025 | 2.45 | 0.12 | 5.15% | 2.33 | 2.51 | 2.31 |
| Mar 17, 2025 | 2.36 | 0.06 | 2.61% | 2.30 | 2.50 | 2.27 |
| Mar 14, 2025 | 2.30 | -0.06 | -2.54% | 2.36 | 2.46 | 2.28 |
| Mar 13, 2025 | 2.30 | -0.06 | -2.54% | 2.36 | 2.39 | 2.23 |
| Mar 12, 2025 | 2.38 | 0.08 | 3.48% | 2.30 | 2.42 | 2.27 |
| Mar 11, 2025 | 2.27 | 0.08 | 3.65% | 2.19 | 2.29 | 2.11 |
| Mar 10, 2025 | 2.19 | -0.14 | -6.01% | 2.33 | 2.39 | 2.19 |
| Mar 7, 2025 | 2.36 | 0.02 | 0.85% | 2.34 | 2.42 | 2.30 |
| Mar 6, 2025 | 2.35 | -0.01 | -0.42% | 2.36 | 2.44 | 2.29 |
| Mar 5, 2025 | 2.38 | -0.14 | -5.56% | 2.52 | 2.65 | 2.34 |
| Mar 4, 2025 | 2.53 | 0.34 | 15.53% | 2.19 | 2.54 | 2.14 |
| Mar 3, 2025 | 2.23 | -0.17 | -7.08% | 2.40 | 2.45 | 2.19 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Heron Therapeutics, Inc. Company profile
About Heron Therapeutics Inc
Heron Therapeutics, Inc. is a commercial-stage biotechnology company. The Company commercializes a portfolio of products to care for acute care and oncology patients. Its oncology care product portfolio includes SUSTOL and CINVANTI. SUSTOL is used for the prevention of acute and delayed nausea and vomiting associated with both moderately emetogenic chemotherapy (MEC), and anthracycline and cyclophosphamide (AC) combination chemotherapy regimens. CINVANTI is an intravenous (IV) formulation of aprepitant, a substance P/neurokinin-1 (NK1) receptor antagonist. Its acute care product portfolio includes ZYNRELEF (HTX-011), HTX-019, and HTX-034. HTX-011 is a dual-acting local anaesthetic that delivers a fixed-dose combination of the local anaesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam. HTX-019 is an investigational agent for the prevention of postoperative nausea and vomiting. HTX-034 is a product candidate for postoperative pain management.
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, Heron Therapeutics Inc revenues decreased 3% to $86.3M. Net loss decreased 3% to $220.7M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects "Research and development - Balancing va decrease of 39% to $66.4M (expense), Stock-based Compensation in SGA decrease of 24% to $11.8M (expense).
Equity composition
Common Stock $.01 Par, 02/10, 50M auth., 40,143,227 issd. Insiders own 6.70%. IPO: 8/87, 2M shares @ $7.00 by Allen & Co. 2/92, private placement of 1,150,000 units (1 Share + 1 Warrant). 5/01, Name changed from Advanced Polymer Systems, Inc. FY'01 fncls. are restated. 05/07, 1-for-4 reverse stock split. 01/14, 1-for-20 Reverse stock split.
| Industry: | Biotechnology & Medical Research (NEC) |
4242 Campus Point Court, Suite 200
SAN DIEGO
CALIFORNIA 92121
US
News
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025
Coffee price forecast: 2025-2030 third-party coffee target
Coffee prices have cooled considerably in the past few months. Is a rebound in store or will they continue to fall?
09:42, 12 March 2025
The Simpsons predicted XRP to hit $589: Has the show got it right again?
Did the animated TV show predict a breakout for the XRP cryptocurrency?
11:00, 11 March 2025
Rolls-Royce share price forecast: third- party price target
Our Rolls-Royce share price forecast looks at the outlook for the FTSE 100-listed engineering company after a tough few years.
14:58, 10 March 2025
Gasoline petrol price forecast 2025-2030: Third-party price target
Discover third-party gasoline (petrol) price predictions for 2025 and beyond, with analyst targets, historical prices, and trading strategies.
10:27, 3 March 2025
USD forecast - third party data round up
The DXY hit a seven-month low in January, just a few months after a multi-decade peak in late September.
10:02, 27 February 2025
Microsoft Stock Price Forecast for 2025 and beyond: Third party price target
We assess the likely level of the Microsoft stock price in 5 years, and possible drivers behind the stock’s past performance. Read on...
18:29, 7 February 2025People also watch
Still looking for a broker you can trust?
Join the 710,000+ traders worldwide that chose to trade with Capital.com